These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 34985313)

  • 41. Biodistribution and first clinical results of
    Ilhan H; Lindner S; Todica A; Cyran CC; Tiling R; Auernhammer CJ; Spitzweg C; Boeck S; Unterrainer M; Gildehaus FJ; Böning G; Jurkschat K; Wängler C; Wängler B; Schirrmacher R; Bartenstein P
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):870-880. PubMed ID: 31492994
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Prospective Observational Study to Evaluate the Effects of Long-Acting Somatostatin Analogs on
    Gålne A; Almquist H; Almquist M; Hindorf C; Ohlsson T; Nordenström E; Sundlöv A; Trägårdh E
    J Nucl Med; 2019 Dec; 60(12):1717-1723. PubMed ID: 31000584
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment modalities favoring outcome in well-differentiated neuroendocrine tumors G3.
    Hinterleitner M; Pfeiffer R; Trautwein NF; Sipos B; Singer S; Nadalin S; Königsrainer A; Lauer UM; la Fougère C; Zender L; Hinterleitner C
    Front Endocrinol (Lausanne); 2023; 14():1285529. PubMed ID: 38260136
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Appropriate use of morphological imaging for assessing treatment response and disease progression of neuroendocrine tumors.
    Ronot M; Dioguardi Burgio M; Gregory J; Hentic O; Vullierme MP; Ruszniewski P; Zappa M; de Mestier L
    Best Pract Res Clin Endocrinol Metab; 2023 Sep; 37(5):101827. PubMed ID: 37858478
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PET/TC imaging with somatostatin analogues for assessment of neuroendocrine tumors, initial experience.
    Suárez-Piñera M; Visa Turno L; Ilzarbe L; Zugazaga A; Poves I; Mestre-Fusco A; Iglesias M
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(6):382-385. PubMed ID: 30826325
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Somatostatin receptor PET beyond the neuroendocrine tumors of the gastrointestinal tract - the review of literature.
    Zogala D
    Klin Onkol; 2021; 34(4):291-299. PubMed ID: 34905930
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Metastatic Medullary Thyroid Cancer: The Role of 68Gallium-DOTA-Somatostatin Analogue PET/CT and Peptide Receptor Radionuclide Therapy.
    Hayes AR; Crawford A; Al Riyami K; Tang C; Bomanji J; Baldeweg SE; Wild D; Morganstein D; Harry A; Grozinsky-Glasberg S; Oleinikov K; Khoo B; Caplin ME; Nicolas GP; Grossman AB
    J Clin Endocrinol Metab; 2021 Nov; 106(12):e4903-e4916. PubMed ID: 34379772
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Small Bowel Neuroendocrine Neoplasms-A Review.
    Vulasala SS; Virarkar M; Gopireddy D; Waters R; Alkhasawneh A; Awad Z; Maxwell J; Ramani N; Kumar S; Onteddu N; Morani AC
    J Comput Assist Tomogr; 2024 Jul-Aug 01; 48(4):563-576. PubMed ID: 38110305
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Application and Dosimetric Requirements for Gallium-68-labeled Somatostatin Analogues in Targeted Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors.
    Taïeb D; Garrigue P; Bardiès M; Abdullah AE; Pacak K
    PET Clin; 2015 Oct; 10(4):477-86. PubMed ID: 26384594
    [TBL] [Abstract][Full Text] [Related]  

  • 50.
    Hicks RJ; Jackson P; Kong G; Ware RE; Hofman MS; Pattison DA; Akhurst TA; Drummond E; Roselt P; Callahan J; Price R; Jeffery CM; Hong E; Noonan W; Herschtal A; Hicks LJ; Hedt A; Harris M; Paterson BM; Donnelly PS
    J Nucl Med; 2019 Jun; 60(6):777-785. PubMed ID: 30442752
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The radionuclide molecular imaging and therapy of neuroendocrine tumors.
    Li S; Beheshti M
    Curr Cancer Drug Targets; 2005 Mar; 5(2):139-48. PubMed ID: 15810878
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Clinical significance of neuroendocrine tumors : Incidence, symptoms, diagnosis, stage, and prognostic factors and their influence on disease management].
    Hartrampf PE; Serfling SE; Higuchi T; Bojunga J; Weich A; Werner RA
    Radiologie (Heidelb); 2024 Jul; 64(7):536-545. PubMed ID: 38777918
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance.
    Chan DL; Pavlakis N; Schembri GP; Bernard EJ; Hsiao E; Hayes A; Barnes T; Diakos C; Khasraw M; Samra J; Eslick E; Roach PJ; Engel A; Clarke SJ; Bailey DL
    Theranostics; 2017; 7(5):1149-1158. PubMed ID: 28435454
    [No Abstract]   [Full Text] [Related]  

  • 54. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.
    Putzer D; Kroiss A; Waitz D; Gabriel M; Traub-Weidinger T; Uprimny C; von Guggenberg E; Decristoforo C; Warwitz B; Widmann G; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):364-72. PubMed ID: 23151915
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Current status of PET imaging of neuroendocrine tumours ([18F]FDOPA, [68Ga]tracers, [11C]/[18F]-HTP).
    Ambrosini V; Morigi JJ; Nanni C; Castellucci P; Fanti S
    Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):58-69. PubMed ID: 25677589
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.
    Kulkarni HR; Baum RP
    PET Clin; 2014 Jan; 9(1):83-90. PubMed ID: 25029937
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Current status and future prospects of PET-imaging applications in patients with gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs).
    Papadakis GZ; Karantanas AH; Marias K; Millo C
    Eur J Radiol; 2021 Oct; 143():109932. PubMed ID: 34482177
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Miscellaneous cancers (lung, thyroid, renal cancer, myeloma, and neuroendocrine tumors): role of SPECT and PET in imaging bone metastases.
    Chua S; Gnanasegaran G; Cook GJ
    Semin Nucl Med; 2009 Nov; 39(6):416-30. PubMed ID: 19801221
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Detection rate of unknown primary tumour by using somatostatin receptor PET/CT in patients with metastatic neuroendocrine tumours: a meta-analysis.
    De Dosso S; Treglia G; Pascale M; Tamburello A; Santhanam P; Kroiss AS; Pereira Mestre R; Saletti P; Giovanella L
    Endocrine; 2019 Jun; 64(3):456-468. PubMed ID: 31004334
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET.
    Binderup T; Knigge U; Loft A; Mortensen J; Pfeifer A; Federspiel B; Hansen CP; Højgaard L; Kjaer A
    J Nucl Med; 2010 May; 51(5):704-12. PubMed ID: 20395333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.